We examined the roles of cell- and antibody-mediated immunity in urease vaccine–induced protection against Helicobacter pylori infection. Normal and knockout mice deficient in major histocompatibility complex (MHC) class I, MHC class II, or B cell responses were mucosally immunized with urease plus Escherichia coli heat-labile enterotoxin (LT), or parenterally immunized with urease plus aluminum hydroxide or a glycolipid adjuvant, challenged with H. pylori strain X47-2AL, and H. pylori organisms and leukocyte infiltration in the gastric mucosa quantified. In an adjuvant/route study in normal mice, there was a direct correlation between the level of protection and the density of T cells recruited to the gastric mucosa. In knockout studies, oral immunization with urease plus LT protected MHC class I knockout mice [β2-microglobulin (−/−)] but not MHC class II knockout mice [I-Ab (−/−)]. In B cell knockout mice [μMT (−/−)], vaccine-induced protection was equivalent to that observed in immunized wild-type (+/+) mice; no IgA+ cells were detected in the stomach, but levels of CD4+ cells equivalent to those in the wild-type strain (+/+) were seen. These studies indicate that protection of mice against H. pylori infection by immunization with the urease antigen is dependent on MHC class II–restricted, cell-mediated mechanisms, and antibody responses to urease are not required for protection.
Skip Nav Destination
Article navigation
21 December 1998
Article|
December 21 1998
Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses
Thomas H. Ermak,
Thomas H. Ermak
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Paul J. Giannasca,
Paul J. Giannasca
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Richard Nichols,
Richard Nichols
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Gwendolyn A. Myers,
Gwendolyn A. Myers
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
John Nedrud,
John Nedrud
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Richard Weltzin,
Richard Weltzin
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Cynthia K. Lee,
Cynthia K. Lee
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Harold Kleanthous,
Harold Kleanthous
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Thomas P. Monath
Thomas P. Monath
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Search for other works by this author on:
Thomas H. Ermak
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Paul J. Giannasca
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Richard Nichols
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Gwendolyn A. Myers
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
John Nedrud
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Richard Weltzin
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Cynthia K. Lee
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Harold Kleanthous
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Thomas P. Monath
From *OraVax, Inc., Cambridge, Massachusetts 02139; and ‡Case Western Reserve University, Cleveland, Ohio 44106
Address correspondence to Thomas Ermak, OraVax, Inc., 38 Sidney St., Cambridge, MA 02139. Phone: 617-494-1339; Fax: 617-494-0927; E-mail: [email protected]
Received:
June 09 1998
Revision Received:
October 13 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (12): 2277–2288.
Article history
Received:
June 09 1998
Revision Received:
October 13 1998
Citation
Thomas H. Ermak, Paul J. Giannasca, Richard Nichols, Gwendolyn A. Myers, John Nedrud, Richard Weltzin, Cynthia K. Lee, Harold Kleanthous, Thomas P. Monath; Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses . J Exp Med 21 December 1998; 188 (12): 2277–2288. doi: https://doi.org/10.1084/jem.188.12.2277
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement